Since deregulated STAT3 signaling has a major impact on CTCL initiation and progression, a better understanding of the molecular basis of the miR-124/STAT3 axis may provide useful information for future personalized therapies. Here, STAT3 is linked to primary cutaneous T-cell non-Hodgkin lymphoma.